LOS ANGELES, Oct. 20, 2022 (GLOBE NEWSWIRE) — The law firm of Portnoy Centessa Pharmaceuticals plc (“Centessa” or the “Company”) (NASDAQ: CNTA) announces that it has filed a class action lawsuit on behalf of investors. Centessa investors who have lost money investing are encouraged to do so Contact Lesley Portnoy, Esq.

Investors are encouraged to contact an attorney Lesley F Portnoyby phone 844-767-8529 or E-mail: [email protected] to discuss your legal rights, or click here to join the case about www.portnoylaw.com. Portnoy Law Firm can provide a free case assessment and discuss investors’ options for making claims to recover their losses.

The complaint alleges that the offering documents were negligently prepared and, as a result, contained untrue statements about material facts or failed to state other facts necessary for the statements made not to be misleading and that they were not in accordance with the Rules and rules for their creation have been drawn up . In addition, during the Class Period, the Defendants made materially false and misleading statements about the Company’s business, operations and prospects. In particular, the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose the following: (i) lixivaptan was less safe than Defendants had claimed; (ii) Defendants have overstated the clinical and commercial prospects of lixivaptan; (iii) ZF874 was less safe than defendants had argued; (iv) Defendants exaggerated ZF874’s clinical and commercial prospects while downplaying the drug’s safety issues; and (v) as a result, the offering materials and the Company’s public statements during the Class Period were materially false and/or misleading and did not contain information required to be disclosed therein.

On November 1, 2021, Centessa issued a press release announcing the results of the Phase 1 study evaluating ZF874 in the treatment of AATD, including but not limited to potential safety issues…